Rationale and Dose Regimen for Sitagliptin/ Glimepiride Combination Therapy in Type 2 Diabetes Treatment

Authors

  • Mohammed Hamid Mohammed
  • Orooba Mohammed Saeed Ibrahim

DOI:

https://doi.org/10.37506/ijfmt.v15i3.15981

Keywords:

monotherapies, synergistic, insulin, GLP-1.

Abstract

This study explores how glimepiride, alone or in combination with sitagliptin, affected glycemic control in
Type 2 diabetes patients. Type 2 diabetes was induced in rats by feeding them a high-fat diet and injecting
them with Alloxan and nicotinamide. Forty-two rats were divided equally into seven groups. Negative
control and group 2-7: rats fed with the HFD Positive control (diabetic non-treated) Group (T1, T2, T3, T4
and T5) were treated with monotherapy and combination. All the treatment regimen reduces fasting blood
glucose and enhanced GLP-1 and insulin level as indicated by an increase in the area under the curve.
Additionally, as opposed to monotherapies, the combination category had better glycemic regulation. As a
result, we assume that sitagliptin/glimepiride combined therapy has a synergistic effect.

Author Biographies

Mohammed Hamid Mohammed

Lecture, Department of Physiology, Biochemistry, and Pharmacology, College of Veterinary Medicine,
University of Baghdad, Iraq

Orooba Mohammed Saeed Ibrahim

Prof. Department of Physiology, Biochemistry, and Pharmacology, College of Veterinary Medicine,
University of Baghdad, Iraq

Published

2021-05-17

How to Cite

Mohammed, M. H., & Saeed Ibrahim, O. M. . (2021). Rationale and Dose Regimen for Sitagliptin/ Glimepiride Combination Therapy in Type 2 Diabetes Treatment. Indian Journal of Forensic Medicine & Toxicology, 15(3), 4396-4403. https://doi.org/10.37506/ijfmt.v15i3.15981